Price History

Hover for the daily close. The dotted line marks the period open.

Compare AVXL with… →

AVXL Key Statistics

As of Sep 4, 2026

Trading

Open: $2.82
Previous Close: $2.85
Day's Range: 2.81–2.91
52-Week Range: 2.26–10.40
Volume: 307.10K
Beta: 1.14

Valuation

Market Cap: $265.11M
P/E Ratio: unprofitable
EPS (ttm): −0.14

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$46.38M
Profit margin: 0.00%
Shares Outstanding: 92.70M
1-Year Return: −69.44%

Dividend and dates

Earnings Date: November 24, 2026estimated
Avg Volume: 1.12M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

AVXL Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+221.11%−66.85%−19.66%

2016*2017201820192020202120222023202420252026*

Year	Return
2026 (partial year)	−19.66%
2025	−66.85%
2024	+15.36%
2023	+0.54%
2022	−46.60%
2021	+221.11%
2020	+108.49%
2019	+66.03%
2018	−51.55%
2017	−18.69%
2016 (partial year)	+24.92%

As of September 4, 2026.

AVXL Revenue and Earnings by Fiscal Year

FY ends September

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$46.38M	—
2024	$0.00	−$43.00M	—
2023	$0.00	−$47.51M	—
2022	$0.00	−$47.98M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$51.37M	−$46.38M	—
2024	$0.00	—	−$52.80M	−$43.00M	—
2023	$0.00	—	−$55.74M	−$47.51M	—
2022	$0.00	—	−$50.99M	−$47.98M	—

Annual figures as reported, in the company's reporting currency. As of September 30, 2025.

AVXL Valuation vs Biotechnology Median

Median of 656 stocks

Metric	AVXL	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Anavex Life Sciences Corp. (AVXL) at $265.11M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 34.

AVXL last closed at $2.86 on September 4, 2026. That is +$0.01 (+0.35%) against the previous close. The 52-week range on file runs from $2.26 to $10.40. The latest close sits 26.83% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $46.38M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −0.14.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Over the trailing twelve months the price has returned −69.44%. Across 10 years the annualized return works out at −0.64%. The reported beta is 1.14. Daily returns over the trailing 10 years annualize to a volatility of 83.64%.

Growth & Income

The record shows no dividend for AVXL.

Across the complete calendar years on file, 2021 returned +221.11% and 2025 returned −66.85%. Of the 9 complete calendar years on file, 5 finished higher. So far in 2026 the price is −19.66%.

Peer Comparison

Anavex Life Sciences Corp. (AVXL) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Anavex Life Sciences Corp.	AVXL	$265.11M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Anavex Life Sciences Corp. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.

Visit website →

Anavex Life Sciences Corp. (AVXL) Stock Analysis